ARCT-032
Phase 1Biologic
ARCT-032 is one of 33 biologic programs targeting Cystic Fibrosis. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Onglyza
AstraZenecaPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Actimmune
HHorizon Therapeutics Ireland DAC
Preclinical
Aztreonam Lysine
GileadPreclinical
Advil
KKenvue Brands
Preclinical
Capromorelin
UUniversity of Aarhus
Preclinical
Amitiza
SSucampo Pharma Americas, LLC
Preclinical
Serevent
GGlaxo Dba Glaxosmithkline
Preclinical
Tums
OtsukaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ARCT-032. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- AArcturus Therapeutics, Inc.